Bye-bye Chiro-inositol - Myo-inositol: True progress in the treatment of polycystic ovary syndrome and ovulation induction

European Review for Medical and Pharmacological Sciences

Volumn 15, Issue 10, 2011, Pages 1212-1214

  Galletta, Marco ^a   Grasso, S ^a   Vaiarelli, A ^b   Roseff, Scott J ^c  

^a Hera Association   (Italy)

^b UNIVERSITY OF MESSINA   (Italy)

^c Palm Beach Center for Reproductive Medicine   (United States)

Author keywords

Chiro inositol; Myo inositol; Polycystic ovary syndrome

Indexed keywords

D CHIRO INOSITOL; INOSITOL; INSULIN SENSITIZING AGENT; UNCLASSIFIED DRUG;

HUMAN; INSULIN SENSITIVITY; OOCYTE; OVARY FOLLICLE FLUID; OVARY POLYCYSTIC DISEASE; REVIEW;

FEMALE; HUMANS; INOSITOL; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME;

EID: 82455167072     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. BROMBERG WJ, EDLICH RF. Joseph Larner's personal Odyssey: search for the cause and cure of non-insulin-dependent diabetes mellitus. J Emerg Med 1994; 12: 681-684.
2. LARNER J. D-chiro-inositol - its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res 2002; 3: 47-60.
3. NESTLER JE, JAKUBOWICZ DJ, REAMER P, GUNN RD, ALLAN G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999; 340: 1314-1320.
4. IUORNO MJ, JAKUBOWICZ DJ, BAILLARGEON JP, DILLON P, GUNN RD, ALLAN G, NESTLER JE. Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome. Endocr Pract 2002; 8: 417-423.
5. BAILLARGEON JP, IUORNO MJ, JAKUBOWICZ DJ, APRIDONIDZE T, HE N, NESTLER JE. Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004; 89: 242-249.
6. BAILLARGEON JP, DIAMANTI-KANDARAKIS E, OSTLUND RE, JR., APRIDONIDZE T, IUORNO MJ, NESTLER JE. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 2006; 29: 300-305.
7. CHEANG KI, BAILLARGEON JP, ESSAH PA, OSTLUND RE, JR., APRIDONIZE T, ISLAM L, NESTLER JE. Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism 2008; 57: 1390-1397.
8. GERLI S, PAPALEO E, FERRARI A, DI RENZO GC. Randomized, double blind placebo-controlled trial: effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci 2007; 11: 347-354.
9. PAPALEO E, UNFER V, BAILLARGEON JP, DE SANTIS L, FUSI F, BRIGANTE C, MARELLI G, CINO I, REDAELLI A, FERRARI A. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol 2007; 23: 700-703.
10. GENAZZANI AD, LANZONI C, RICCHIERI F, JASONNI VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008; 24: 139-144.
11. MINOZZI M, D'ANDREA G, UNFER V. Treatment of hirsutism with myo-inositol: a prospective clinical study. Reprod Biomed Online 2008; 17: 579-582.
12. ZACCHE MM, CAPUTO L, FILIPPIS S, ZACCHE G, DINDELLI M, FERRARI A. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol 2009; 25: 508-513.
13. COSTANTINO D, MINOZZI G, MINOZZI E, GUARALDI C. Metabolic and hormonal effects of myo-inositol in women with polycystic ovary syndrome: a double-blind trial. Eur Rev Med Pharmacol Sci 2009; 13: 105-110.
14. PAPALEO E, UNFER V, BAILLARGEON JP, FUSI F, OCCHI F, DE SANTIS L. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 2009; 91: 1750-1754.
15. RIZZO P, RAFFONE E, BENEDETTO V. Effect of the treatment with myo-inositol plus folic acid plus melatonin in comparison with a treatment with myo-inositol plus folic acid on oocyte quality and pregnancy outcome in IVF cycles. A prospective, clinical trial. Eur Rev Med Pharmacol Sci 2010; 14: 555-561.
16. SUN TH, HEIMARK DB, NGUYGEN T, NADLER JL, LARNER J. Both myo-inositol to chiro-inositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Biophys Res Commun 2002; 293: 1092-1098.
17. LARNER J, CRAIG JW. Urinary myo-inositol-to-chiro-inositol ratios and insulin resistance. Diabetes Care 1996; 19: 76-78.
18. KENNINGTON AS, HILL CR, CRAIG J, BOGARDUS C, RAZ I, ORTMEYER HK, HANSEN BC, ROMERO G, LARNER J. Low urinary chiro-inositol excretion in non-insulin-dependent diabetes mellitus. N Engl J Med 1990; 323: 373-378.
19. ASPLIN I, GALASKO G, LARNER J. chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol- and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc Natl Acad Sci U S A 1993; 90: 5924-5928.
20. HARWOOD K, VUGUIN P, DIMARTINO-NARDI J. Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. Horm Res 2007; 68: 209-217.
21. MATALLIOTAKIS I, KOURTIS A, KOUKOURA O, PANIDIS D. Polycystic ovary syndrome: etiology and pathogenesis. Arch Gynecol Obstet 2006; 274: 187-197.
22. RICE S, CHRISTOFORIDIS N, GADD C, NIKOLAOU D, SEYANI L, DONALDSON A, MARGARA R, HARDY K, FRANKS S. Impaired insulin-dependent glucose metabolism in granulosa-lutein cells from anovulatory women with polycystic ovaries. Hum Reprod 2005; 20: 373-381.
23. CARLOMAGNO G, UNFER V, ROSEFF S. The D-chiro-inositol paradox in the ovary. Fertil Steril 2011; 95: 2515-2516.
24. CHATTOPADHAYAY R, GANESH A, SAMANTA J, JANA SK, CHAKRAVARTY BN, CHAUDHURY K. Effect of follicular fluid oxidative stress on meiotic spindle formation in infertile women with polycystic ovarian syndrome. Gynecol Obstet Invest 2010; 69: 197-202.